Mylan has launched in the US a generic version of Mylan’s Exelon (rivastigmine) 4.6mg/24-hour, 9.5mg/24-hour and 13.3mg/24- hour transdermal patches, after receiving approval from the US Food and Drug Administration (FDA).
Citing Iqvia data, Mylan observed that the rivastigmine transdermal system in the three doses had US sales of approximately US$248...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?